MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
1.018
+0.018
+1.84%
Opening 10:15 04/18 EDT
OPEN
0.9900
PREV CLOSE
1.000
HIGH
1.018
LOW
0.9900
VOLUME
6.35K
TURNOVER
0
52 WEEK HIGH
3.950
52 WEEK LOW
0.6500
MARKET CAP
44.08M
P/E (TTM)
-1.0135
1D
5D
1M
3M
1Y
5Y
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio, Inc. Is a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies. William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on April 18th.
Barchart · 2d ago
Weekly Report: what happened at INAB last week (0408-0412)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 5d ago
Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform
TipRanks · 6d ago
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)
TipRanks · 04/10 16:50
IN8bio Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 04/10 15:01
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
Benzinga · 04/10 14:51
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Webull offers IN8BIO, Inc. stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.